losartan has been researched along with lenvatinib in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akahane, T; Ishida, K; Kaji, K; Kawaratani, H; Mitoro, A; Moriya, K; Namisaki, T; Nishimura, N; Ogawa, H; Takagi, H; Takaya, H; Yoshiji, H | 1 |
1 other study(ies) available for losartan and lenvatinib
| Article | Year |
|---|---|
The Angiotensin II Receptor Blocker Losartan Sensitizes Human Liver Cancer Cells to Lenvatinib-Mediated Cytostatic and Angiostatic Effects.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Cytostatic Agents; Humans; Liver Neoplasms; Losartan; Mice; Phenylurea Compounds; Quinolines | 2021 |